Log in

ASX:LCTLiving Cell Technologies Competitors & Alternatives

A$0.01
0.00 (0.00 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$0.01
Now: A$0.01
A$0.01
50-Day Range
A$0.01
MA: A$0.01
A$0.01
52-Week Range
A$0.01
Now: A$0.01
A$0.04
Volume76,622 shs
Average VolumeN/A
Market Capitalization$7.43 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Living Cell Technologies (ASX:LCT) Vs. RZLT, KZA, NBY, NOX, PBT, and SCLP

Should you be buying LCT stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Living Cell Technologies, including Rezolute (RZLT), Kazia Therapeutics (KZA), NovaBay Pharmaceuticals (NBY), Noxopharm (NOX), Prana Biotechnology (PBT), and Scancell (SCLP).

Living Cell Technologies (ASX:LCT) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Profitability

This table compares Living Cell Technologies and Rezolute's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Living Cell TechnologiesN/AN/AN/A
RezoluteN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Living Cell Technologies and Rezolute, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Living Cell Technologies0000N/A
Rezolute00203.00

Rezolute has a consensus price target of $0.4650, suggesting a potential upside of 365.00%. Given Rezolute's higher possible upside, analysts plainly believe Rezolute is more favorable than Living Cell Technologies.

Earnings and Valuation

This table compares Living Cell Technologies and Rezolute's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Living Cell Technologies$708,094.0010.49$-1,714,323.07A$0.00-4.33
RezoluteN/AN/AN/AN/AN/A

Rezolute has lower revenue, but higher earnings than Living Cell Technologies.

Summary

Rezolute beats Living Cell Technologies on 2 of the 3 factors compared between the two stocks.

Kazia Therapeutics (ASX:KZA) and Living Cell Technologies (ASX:LCT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, institutional ownership and risk.

Valuation and Earnings

This table compares Kazia Therapeutics and Living Cell Technologies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kazia Therapeutics$1.40 million20.66$-11,474,505.94A($0.16)-2.52
Living Cell Technologies$708,094.0010.49$-1,714,323.07A$0.00-4.33

Living Cell Technologies has lower revenue, but higher earnings than Kazia Therapeutics. Living Cell Technologies is trading at a lower price-to-earnings ratio than Kazia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Kazia Therapeutics and Living Cell Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kazia Therapeutics0000N/A
Living Cell Technologies0000N/A

Profitability

This table compares Kazia Therapeutics and Living Cell Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kazia TherapeuticsN/AN/AN/A
Living Cell TechnologiesN/AN/AN/A

Summary

Kazia Therapeutics beats Living Cell Technologies on 3 of the 5 factors compared between the two stocks.

Living Cell Technologies (ASX:LCT) and NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Living Cell Technologies and NovaBay Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Living Cell Technologies0000N/A
NovaBay Pharmaceuticals00103.00

NovaBay Pharmaceuticals has a consensus price target of $1.10, suggesting a potential upside of 1.85%. Given NovaBay Pharmaceuticals' higher possible upside, analysts plainly believe NovaBay Pharmaceuticals is more favorable than Living Cell Technologies.

Earnings & Valuation

This table compares Living Cell Technologies and NovaBay Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Living Cell Technologies$708,094.0010.49$-1,714,323.07A$0.00-4.33
NovaBay PharmaceuticalsN/AN/AN/AN/AN/A

NovaBay Pharmaceuticals has lower revenue, but higher earnings than Living Cell Technologies.

Profitability

This table compares Living Cell Technologies and NovaBay Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Living Cell TechnologiesN/AN/AN/A
NovaBay PharmaceuticalsN/AN/AN/A

Summary

NovaBay Pharmaceuticals beats Living Cell Technologies on 2 of the 3 factors compared between the two stocks.

Noxopharm (ASX:NOX) and Living Cell Technologies (ASX:LCT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Earnings & Valuation

This table compares Noxopharm and Living Cell Technologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Noxopharm$4.25 million6.63$-18,122,034.00A($0.12)-1.55
Living Cell Technologies$708,094.0010.49$-1,714,323.07A$0.00-4.33

Living Cell Technologies has lower revenue, but higher earnings than Noxopharm. Living Cell Technologies is trading at a lower price-to-earnings ratio than Noxopharm, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Noxopharm and Living Cell Technologies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Noxopharm0000N/A
Living Cell Technologies0000N/A

Profitability

This table compares Noxopharm and Living Cell Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NoxopharmN/AN/AN/A
Living Cell TechnologiesN/AN/AN/A

Summary

Living Cell Technologies beats Noxopharm on 3 of the 5 factors compared between the two stocks.

Prana Biotechnology (ASX:PBT) and Living Cell Technologies (ASX:LCT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares Prana Biotechnology and Living Cell Technologies' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prana Biotechnology$4.34 million0.00$-10,782,518.85A($0.02)N/A
Living Cell Technologies$708,094.0010.49$-1,714,323.07A$0.00-4.33

Living Cell Technologies has lower revenue, but higher earnings than Prana Biotechnology. Living Cell Technologies is trading at a lower price-to-earnings ratio than Prana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Prana Biotechnology and Living Cell Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prana BiotechnologyN/AN/AN/A
Living Cell TechnologiesN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and target prices for Prana Biotechnology and Living Cell Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prana Biotechnology0000N/A
Living Cell Technologies0000N/A

Living Cell Technologies (ASX:LCT) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Analyst Ratings

This is a summary of recent ratings and target prices for Living Cell Technologies and Scancell, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Living Cell Technologies0000N/A
Scancell0000N/A

Profitability

This table compares Living Cell Technologies and Scancell's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Living Cell TechnologiesN/AN/AN/A
ScancellN/AN/AN/A

Valuation & Earnings

This table compares Living Cell Technologies and Scancell's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Living Cell Technologies$708,094.0010.49£-1,714,323.07A$0.00-4.33
ScancellN/AN/AN/AGBX (1.20)-4.71

Scancell has lower revenue, but higher earnings than Living Cell Technologies. Scancell is trading at a lower price-to-earnings ratio than Living Cell Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Living Cell Technologies beats Scancell on 3 of the 3 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
RZLT
Rezolute
1.2$0.10flat$29.66 millionN/A0.00
KZA
Kazia Therapeutics
1.1$0.40flat$28.87 million$1.40 million-2.52High Trading Volume
NovaBay Pharmaceuticals logo
NBY
NovaBay Pharmaceuticals
0.8$1.08flat$28.80 millionN/A0.00
NOX
Noxopharm
0.4$0.19flat$28.17 million$4.25 million-1.55High Trading Volume
PBT
Prana Biotechnology
0.5N/AN/A$27.81 million$4.34 million-2.58
Scancell logo
SCLP
Scancell
0.6$5.65flat£26.29 millionN/A-4.71
ARMP
Armata Pharmaceuticals
1.3$3.96flat$26.13 millionN/A0.00
HEPA
ContraVir Pharmaceuticals
0.6$2.84flat$25.63 millionN/A0.00
FAB
Fusion Antibodies
0.5$102.00flat£25.42 million£3.28 million-22.67
BGT
Bio-Gene Technology
1.1$0.19flat$25.25 million$1.07 million-11.88High Trading Volume
Heavy News Reporting
Tissue Regenix Group logo
TRX
Tissue Regenix Group
0.7$0.35flat£24.61 million£13.03 million-0.58High Trading Volume
NBY
NovaBay Pharmaceuticals
0.8$1.08flat$23.94 millionN/A0.00High Trading Volume
OGEN
Oragenics
1.1$0.75flat$23.89 millionN/A0.00High Trading Volume
BNO
Bionomics
0.6$0.04flat$23.42 million$10.15 million-4.30
HEMO
Hemogenyx Pharmaceuticals
0.4$6.20flat£23.42 millionN/A-15.50
ImmuPharma logo
IMM
ImmuPharma
0.7$12.88flat£22.88 million£77,925.00-3.22Heavy News Reporting
ACR
Acrux
0.6$0.14flat$22.74 million$3.39 million-2.01
QPT
Quest PharmaTech
0.4$0.16flatC$21.76 millionC$38,871.00-5.00
CZO
Ceapro
0.4$0.55flatC$21.65 millionC$13.96 million68.75
SBTX
Skinbiotherapeutics
0.4$16.75flat£21.45 millionN/A-15.23
ACW
Actinogen Medical
0.5$0.02flat$21.21 million$5.73 million-3.17High Trading Volume
EX1
Exopharm
0.6$0.21flat$20.05 million$38,871.00-3.23High Trading Volume
AOR
AorTech International
0.5$113.50flat£19.02 million£539,000.00-30.68High Trading Volume
SLS
Galena Biopharma
0.5$2.78flat$18.67 millionN/A0.00
BTC
BTC Health
0.5$0.08flat$18.46 million$394,156.00-25.00High Trading Volume
C4XD
C4X Discovery
0.6$14.50flat£18.18 million£7.06 million-1.04High Trading Volume
RGS
Regeneus
0.5$0.07flat$18.06 million$1.45 million-3.25High Trading Volume
CDY
Cellmid
1.1$0.19flat$17.87 million$7.65 million-4.02High Trading Volume
Heavy News Reporting
PTX
Prescient Therapeutics
0.6$0.04flat$17.35 million$1.54 million-3.67High Trading Volume
NFX
Nuformix
0.5$3.30flat£17.16 million£535,000.00-16.50High Trading Volume
INTI
Inhibitor Therapeutics
0.3$0.07flat$16.67 millionN/A0.00
Destiny Pharma logo
DEST
Destiny Pharma
0.5$37.00flat£16.45 million£305,906.00-3.46High Trading Volume
ANIC
Agronomics
0.6$5.25flat£16.01 million£-44,040.00-4.04High Trading Volume
BCDA
Biocardia
0.6$2.35flat$15.75 millionN/A0.00High Trading Volume
CAN-FITE BIOPHA/S logo
CANF
CAN-FITE BIOPHA/S
1.3$2.00flat$15.61 millionN/A0.00Analyst Report
Heavy News Reporting
CANF
Can-Fite Biopharma
0.5$2.00flat$15.43 millionN/A0.00
CTX
Crescita Therapeutics
0.9$0.50flatC$15.12 millionC$21.90 million7.94
IMC
Immuron
0.5$0.09flat$15.06 million$2.97 million-3.04High Trading Volume
KNE
Kane Biotech
0.4$0.15flatC$14.12 millionC$1.53 million-7.89
COS
Collagen Solutions
0.7$3.10flat£13.98 million£4.43 million-7.75
GSD
Devonian Health Group
0.5$0.19flatC$13.96 millionC$2.43 million-3.14
HVO
Hvivo
0.5$16.50flat£13.81 million£12.09 million-0.83
RLM
Realm Therapeutics
0.7N/AN/A£13.41 million£501,919.00-0.66High Trading Volume
BXN
Bioxyne
0.5N/AN/A$12.80 million$2.14 million-20.00High Trading Volume
RNO
Rhinomed
0.5$0.07flat$12.35 million$3.67 million-1.30High Trading Volume
NSP
Naturally Splendid Enterprises
0.6$0.05flatC$11.06 millionC$3.04 million-0.85
MPH
Medicure
1.2N/AN/AC$10.80 millionC$18.30 million-0.82
BTI
biOasis Technologies
0.7$0.36flatC$10.16 millionC$718,475.00-5.14High Trading Volume
Heavy News Reporting
ANR
Anatara Lifesciences
0.5$0.20flat$9.97 million$594,136.00-3.70High Trading Volume
1AD
Adalta
0.5$0.06flat$9.84 million$3.91 million-1.03High Trading Volume
This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.